| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1373457 | Inhibition of human FAAH | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756113 | Cytotoxicity against human HuH7 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1674904 | Solubility of the compound in 0.1 M sodium phosphate buffer at pH 7.4 | 2020 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
| Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors. |
| AID1650817 | Inhibition of human soluble epoxide hydrolase using CMNPC as substrate by fluorescence based assay | 2020 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
| Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility. |
| AID756122 | Inhibition of recombinant MET (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373463 | Competitive inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction assessed as increase in substrate Km using varying CMNPC substrate levels by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756119 | Inhibition of recombinant PDGFRalpha (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756118 | Inhibition of recombinant KDR (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373471 | Inhibition of FAAH in mouse brain microsomes using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756112 | Antiproliferative activity against HUVEC after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373456 | Inhibition of soluble epoxide hydrolase (unknown origin) | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373470 | Inhibition of AADAC (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756124 | Inhibition of recombinant FLT-1 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373474 | Inhibition of FAAH in dog brain microsomes using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756116 | Inhibition of full length recombinant c-RAF (unknown origin) using MEK1 as substrate after 1 hr by luminescence assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756127 | Inhibition of human recombinant soluble epoxide hydrolase assessed as cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxyran-2-yl)methyl] carbonate conversion to 6-methoxy-2-naphthaldehyde preincubated for 5 mins prior to substrate addition by fluo | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1186230 | Inhibition of human recombinant soluble epoxide hydrolase assessed as half-life of enzyme-inhibitor complex by FRET-based ACPU displacement assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID1650815 | Aqueous solubility of compound | 2020 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
| Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility. |
| AID756126 | Inhibition of recombinant ABL-2 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1691499 | Inhibition of human mEH at 50 uM using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay relative to control | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Development of potent inhibitors of the human microsomal epoxide hydrolase. |
| AID1373473 | Inhibition of FAAH in cat brain microsomes using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756123 | Inhibition of recombinant FGFR-2 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373477 | Inhibition of soluble epoxide in rat brain microsomes using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373476 | Inhibition of soluble epoxide in mouse brain microsomes using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1674906 | Inhibition of recombinant human soluble epoxide hydrolase using CMNPC as fluorescent substrate | 2020 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 30, Issue:18
| Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors. |
| AID1373468 | Inhibition of PON2 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373462 | Competitive inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using varying CMNPC substrate levels by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373464 | Inhibition of microsomal epoxide hydrolase (unknown origin) expressed in baculovirus system using CMNMC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373479 | Inhibition of soluble epoxide in dog brain microsomes using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373467 | Inhibition of PON1 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373480 | Inhibition of soluble epoxide in horse brain microsomes using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373460 | Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373478 | Inhibition of soluble epoxide in cat brain microsomes using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756121 | Inhibition of recombinant GSK3alpha (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756114 | Cytotoxicity against human HepG2 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756117 | Inhibition of recombinant PDPK-1 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373459 | Inhibition of human FAAH expressed in baculovirus-infected High Five cells S9 fraction using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373465 | Inhibition of human carboxylesterase 1 expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373466 | Inhibition of human carboxylesterase 2 expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373458 | Inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction using CMNPC substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID756120 | Inhibition of recombinant PDGFRbeta (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373472 | Inhibition of FAAH in rat brain microsomes using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1857694 | Inhibition of human recombinant sEH | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
| Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. |
| AID756125 | Inhibition of recombinant FLT-3 (unknown origin) at 10 uM | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1373469 | Inhibition of PON3 (unknown origin) expressed in baculovirus system using CMNA substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1373475 | Inhibition of FAAH in horse brain microsomes using OMP substrate by fluorescence based assay | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. |
| AID1798579 | Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\ | 2008 | Journal of molecular biology, Sep-12, Volume: 381, Issue:4
| The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |